Drug intelligence / Profile preview

rhamnetin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Rhamnetin is a naturally occurring O-methylated flavonol, classified as a monomethoxyflavone and a methylated derivative of quercetin. It is commonly found in various fruits and vegetables, including cloves, coriander leaves and seeds, apple pomace, peanuts, sour cherries, and radishes. Rhamnetin exhibits potent antioxidant and anti-inflammatory properties. Mechanistically, it exerts its anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines such as TNF-alpha and interleukin-6 (IL-6), suppressing nitric oxide (NO) production in activated macrophages, and modulating key signaling pathways including p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and cyclooxygenase (COX)-2. Rhamnetin has demonstrated protective effects against organ damage in preclinical models of sepsis caused by carbapenem-resistant gram-negative bacteria by reducing inflammatory markers and preserving liver/kidney function[1][3][4][5][6]. Additionally, it has been shown to decrease HMG-CoA reductase gene expression while increasing low-density lipoprotein receptor (LDLR) expression in hepatoma cells[8]. Its potential therapeutic applications are under investigation for inflammatory diseases, sepsis due to resistant bacteria, cancer chemoresistance sensitization strategies—particularly hepatocellular carcinoma—and cholesterol metabolism modulation.

Other names
beta-rhamnocitrin7-methoxyquercetin7-O-methylquercetinquercetin 7-methyl etherquercetin7-methyl etherquercetin-7-methyl ether
02

Targets

RK (Ribokinase)JNK (Mitogen-activated protein kinase kinase kinase family)ERK

Beyond the preview

Go deeper on rhamnetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhamnetin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call